Semaglutide subcutaneous injection: what you need to decide before you start

Why subcutaneous and not another route?

There's a common assumption that injections go into muscle, the kind you might associate with a vaccine in the upper arm. If you've ever wondered exactly how Wegovy differs from that, our page covering whether Wegovy is intramuscular or subcutaneous walks through the distinction in detail. The needle enters the subcutaneous tissue, a layer of fat sitting between skin and muscle, and that distinction matters pharmacologically. Absorption from fatty tissue is slower and more consistent than from muscle, which suits a medicine designed to produce steady week-long action. You can read more about the pharmacokinetic reasons for this on our semaglutide pharmacokinetics page.

The three approved sites (abdomen, thigh, upper arm) all have enough subcutaneous tissue to absorb the dose reliably. Rotating between them, and within each site, prevents localised reactions from repeated needle use in the same spot. Most people settle into a routine fairly quickly. The needle itself is short and fine; the sensation is typically a brief pinch rather than anything more significant.

One misconception worth setting aside: people sometimes worry the injection has to go into a specific precise location to work. It doesn't. Any part of the lower abdomen that you can gently pinch away from the navel, the outer thigh, or the fleshy area of the upper arm will do. The pen's fixed needle length manages the depth.

What the prescriber is weighing up before recommending this route

Deciding whether subcutaneous semaglutide is the right choice involves more than confirming you can hold a pen. A prescriber looks at your weight, your health history, any medicines you currently take, and whether the injection form or an oral alternative better fits your circumstances. The MHRA-approved Wegovy injection is licensed for adults with a BMI of 30 or above, or 27 or above where a weight-related condition such as high blood pressure, type 2 diabetes or obstructive sleep apnoea is present. Lower BMI thresholds apply for some ethnic backgrounds under UK guidance.

The subcutaneous injection form may be preferable where morning routine flexibility is limited, because (unlike the oral tablet) the injection does not require a 30-minute fast before food and drink. For people who prefer to avoid needles entirely, our Wegovy overview explains how the oral tablet option compares. Those already established on treatment through another provider, or considering how long they might stay on it, can find relevant context on long-term use of Wegovy.

The prescriber also reviews any medicines that might interact. Semaglutide slows gastric emptying, which can affect how quickly other oral medicines are absorbed, worth flagging if you take time-sensitive medication. If you are currently taking isotretinoin, our page on Accutane and Wegovy covers what the prescriber will need to consider before approving treatment. Our clinical team covers interactions as part of every consultation assessment.

Starting dose, titration and what to expect in the early weeks

Treatment begins at 0.25 mg weekly. This starting dose exists to let the body adjust rather than to produce weight loss directly, the titration schedule moves through 0.5 mg, 1.0 mg and 1.7 mg before reaching the 2.4 mg maintenance dose, typically over around four months, with a prescriber guiding each step. The MHRA has also approved a 7.2 mg maintenance dose for adults with obesity, delivered via a dedicated single-dose pen approved in April 2026.

In the STEP 1 clinical trial, 68 weeks of subcutaneous semaglutide 2.4 mg produced an average body-weight reduction of around 15% alongside lifestyle changes, as published in the New England Journal of Medicine. That figure is a trial average across participants; individual results vary, and a prescriber will discuss realistic expectations with you based on your own picture.

Gastrointestinal effects (nausea most commonly, and sometimes loose stools or constipation) are most noticeable in the early weeks and often settle as the body adapts. They tend to be more pronounced after dose increases. The NHS semaglutide page lists the full side-effect profile and explains when to seek advice. One genuinely useful point our prescribers pass on: eating smaller portions and avoiding rich, fatty food in the first few weeks makes the adjustment considerably smoother for most people.

Cost context and getting started through a regulated route

Private treatment costs vary between providers and by dose. Since Eli Lilly's September 2025 list-price revision became the reference point for the market, the broader pricing picture for weekly injection treatments has shifted; any quoted price should clearly include the clinical assessment, the prescription and delivery. Headline figures that omit any of those are hard to compare accurately. Our guide on where to buy Wegovy explains what to look for when evaluating a provider.

Any legitimate UK supplier of subcutaneous semaglutide operates through a GPhC-registered pharmacy. You can verify any online pharmacy against the register at pharmacyregulation.org. Sellers offering these medicines without a prior clinical assessment are operating outside the law, and fake pens have caused harm, the MHRA has warned publicly about counterfeit weight-loss injections circulating online. That risk is one of the stronger arguments for using a pharmacy you can verify.

At nume, every consultation for subcutaneous semaglutide is reviewed personally by a GPhC-registered Independent Prescriber. If you'd like to explore whether Wegovy is clinically suitable for you, our clinical team can assess your eligibility. Check your eligibility by starting your free consultation.